Categories
Weight Loss Products

Please Don’t Take Garcinia Cambogia Extract For Weight Loss

From Women’s Health

If there’s one thing that’s been proven time and again, it’s that there is no magic pill for weight loss.

And yet, “quick fixes” keep popping up everywhere…and they’re usually pretty problematic (I see you, detox teas). Another example: garcinia cambogia extract-an ingredient most commonly found in weight-loss supplements.

Uh, what exactly is garcinia cambogia?

Photo credit: libin jose - Getty ImagesPhoto credit: libin jose - Getty Images

Garcinia cambogia-a.k.a. Malabar tamarind-is a fruit commonly grown in India and Southeast Asia, according to the National Center for Complementary and Integrative Health (NCCIH). The rind of the fruit is often used to flavour curries and to preserve food.

That rind, however, also contains a chemical called hydroxycitric acid (HCA), which is where the plant’s weight-loss claims come into play-HCA has been studied for weight loss through appetite suppression, per the NCCIH (which is why supplements that contain garcinia cambogia extract are also thought to help you lose weight).

So…is it true? Can garcinia cambogia help you lose weight?

While, yes, there have been studies on garcinia cambogia and weight loss, they haven’t necessarily been reliable (nor are they recent, for that matter).

In a research review set to be published in 2019, researchers found that only five randomized, controlled studies of garcinia cambogia’s effect on weight loss have been done in the last 50 years, according to Scott Kahan, M.D., M.P.H., director of the National Center for Weight Wellness, who carried out the study. (FYI: there have been more than 14,000 studies on unfounded therapies for weight loss in that time, he says.)

What’s more: In those five studies, participants saw very little weight loss. “The most positive study showed that several months of taking garcinia cambogia may lead to one pound of weight loss, at best,” says Kahan-placebo pills were usually more effective.

Well, is garcinia cambogia harmful?

According to Kahan’s research, there are very few severe side effects of garcina cambogia (he only found a few examples of diarrhea, brain fog and, in rare cases, liver damage). And according to the NCCIH, garcinia cambogia is pretty safe for short-term use (12 weeks or fewer).

But while garcinia cambogia itself may not be terrible, the ingredients it comes packaged with in some weight-loss supplements can be.

In 2017, for example, the Food and Drug Administration (FDA) issued a warning about the weight-loss supplement Fruta Planta Life, which is marketed as “Garcinia Cambogia Premium” and contains garcinia cambogia extract and sibutramine (Meridia), an appetite suppressant that was removed from the market in 2010 due to safety concerns. Sibutramine had been shown to increase the risk of heart attack and stroke, cause jaundice, and trigger seizures-pretty nasty stuff.

Another thing to note: since garcinia cambogia extract diet pills are supplements, not drugs, the FDA doesn’t regulate their use or review their effectiveness or safety unless their use becomes linked to multiple hospitalizations, says Sue Decotiis, M.D., a medical weight-loss expert. That means that it’s up to manufacturers to decide how much garcinia cambogia extract their pills pack, as well as what other health-impacting ingredients (like sibutramine) are added to the mix.

I probably shouldn’t take garcinia cambogia…right?

Uh yeah, it’s best to skip it. Possible side effects aside, Kahan says any weight-loss supplement containing garcinia cambogia is a waste of money.

And honestly, that goes for weight-loss supplements in general. “Unlike medical therapies, supplements and various diets and practices are not bound by strict requirements for clinical evaluation and evidence,” says Kahan, adding that “it’s unlikely that all the advertised claims are true.”

Basically, diet supplements-including ones containing garcinia cambogia-aren’t worth the risk, or money. If you want to lose weight, speak to your doctor first, and focus on combining a healthy, balanced diet with regular exercise, suggests Kahan.

The bottom line: Don’t waste your money on any weight-loss supplements (including ones with garcinia cambogia). At best, they’re ineffective; at worst, they’re harmful.

Categories
Weight Loss Products

Westwood Management Boosted By $11.25 Million Its Dexcom (DXCM) Holding; NUTRAFUELS (NTFU) Sellers Decreased By 32% Their Shorts

DexCom, Inc. (NASDAQ:DXCM) Logo

Westwood Management Corp increased Dexcom Inc. (DXCM) stake by 358.71% reported in 2018Q3 SEC filing. Westwood Management Corp acquired 78,700 shares as Dexcom Inc. (DXCM)’s stock declined 14.95%. The Westwood Management Corp holds 100,640 shares with $14.40 million value, up from 21,940 last quarter. Dexcom Inc. now has $10.08B valuation. The stock decreased 0.99% or $1.13 during the last trading session, reaching $113.48. About 785,142 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 105.85% since December 20, 2017 and is uptrending. It has outperformed by 105.85% the SP500. Some Historical DXCM News: 27/03/2018 – FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes; 17/05/2018 – DexCom Announces Upcoming Conference Presentation; 27/03/2018 – DEXCOM INC – EXPECTS TO LAUNCH DEXCOM G6 CGM SYSTEMLATER THIS YEAR; 22/05/2018 – DEXCOM Short Thesis; 02/05/2018 – DexCom 1Q Adj Loss/Shr 32c; 08/03/2018 – DEXCOM INC – PTAB RULED 2 EARLY PATENTS HELD BY WAVEFORM ARE NOT INVALID, BASED ON CHALLENGES BROUGHT BY CO; 29/03/2018 – Alger Spectra Adds DexCom, Cuts CBS, Buys More Facebook; 17/05/2018 – VP Leach Gifts 176 Of DexCom Inc; 27/03/2018 – U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM; 08/03/2018 WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents

NUTRAFUELS INC (OTCMKTS:NTFU) had a decrease of 32% in short interest. NTFU’s SI was 8,500 shares in December as released by FINRA. Its down 32% from 12,500 shares previously. With 78,600 avg volume, 0 days are for NUTRAFUELS INC (OTCMKTS:NTFU)’s short sellers to cover NTFU’s short positions. It closed at $0.194 lastly. It is down 0.00% since December 20, 2017 and is . It has by 0.00% the SP500.

NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products to retail and wholesale outlets. The company has market cap of $17.58 million. The companyÂ’s products include sleep spray to support a healthy sleep cycle and improve the quality of restful sleep; energize spray to enhance energy, and restore vigor and vitality; and garcinia cambogia spray, an appetite and weight management spray. It currently has negative earnings. It also offers NRG-X extreme energy spray to enhance energy and stamina; headache and pain spray to relieve headaches and pain; and hair, skin, and nails spray to nourish and encourage hair, skin, and nail growth.

More news for NutraFuels, Inc. (OTCMKTS:NTFU) were recently published by: Globenewswire.com, which released: “Freedom Leaf Inc. Announces National Distribution Agreement Other OTC:FRLF – GlobeNewswire” on February 28, 2018. Globenewswire.com‘s article titled: “Freedom Leaf, Inc Partners With NutraFuels, Inc And Attends Tobacco Product Expo (TPE) In Las Vegas, NV – GlobeNewswire” and published on January 31, 2018 is yet another important article.

Among 11 analysts covering DexCom (NASDAQ:DXCM), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. DexCom had 16 analyst reports since July 2, 2018 according to SRatingsIntel. Berenberg upgraded the shares of DXCM in report on Monday, August 6 to “Buy” rating. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Neutral” rating given on Friday, October 19 by Goldman Sachs. Jefferies maintained it with “Buy” rating and $125 target in Thursday, August 2 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, October 11. BMO Capital Markets maintained the stock with “Outperformer” rating in Thursday, August 2 report. The firm earned “Buy” rating on Thursday, August 23 by Canaccord Genuity. Bank of America maintained the stock with “Buy” rating in Wednesday, August 15 report. The firm has “Buy” rating given on Thursday, August 2 by Canaccord Genuity. The firm has “Outperform” rating by Robert W. Baird given on Thursday, August 23. Morgan Stanley maintained it with “Equal-Weight” rating and $130 target in Friday, August 3 report.

Investors sentiment increased to 1.31 in 2018 Q3. Its up 0.09, from 1.22 in 2018Q2. It improved, as 12 investors sold DXCM shares while 107 reduced holdings. 84 funds opened positions while 72 raised stakes. 84.12 million shares or 4.99% less from 88.54 million shares in 2018Q2 were reported. Df Dent And Com Inc reported 0.03% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Baillie Gifford Com holds 0.79% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 5.09 million shares. Susquehanna Intl Gp Llp accumulated 1,552 shares or 0% of the stock. Fiduciary Tru invested in 0.02% or 3,925 shares. Schwab Charles Inv Management Incorporated has 338,177 shares for 0.03% of their portfolio. Barclays Public Limited Liability Corp reported 0.01% stake. Accredited Inc holds 0.08% or 2,367 shares. Alabama-based Weiss Multi has invested 0.15% in DexCom, Inc. (NASDAQ:DXCM). 2,135 were reported by Manufacturers Life Insur Company The. Js Lc, a New York-based fund reported 700 shares. Essex Investment Management Lc stated it has 0.29% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Regions Fincl Corp invested in 0.04% or 23,208 shares. Royal Bankshares Of Canada invested in 138,409 shares or 0.01% of the stock. Moreover, Granahan Mgmt Ma has 0.36% invested in DexCom, Inc. (NASDAQ:DXCM) for 46,596 shares. 765 were reported by Pnc Group Inc Incorporated.

Westwood Management Corp decreased Coherent Inc. (NASDAQ:COHR) stake by 1,900 shares to 224,000 valued at $38.57 million in 2018Q3. It also reduced Texas Instruments Inc. (NASDAQ:TXN) stake by 149,090 shares and now owns 90,600 shares. Delphi Technologies Plc was reduced too.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Categories
Weight Loss Products

Westwood Management Boosted By $11.25 Million Its Dexcom (DXCM) Holding; NUTRAFUELS (NTFU) Sellers Decreased By 32% Their Shorts

DexCom, Inc. (NASDAQ:DXCM) Logo

Westwood Management Corp increased Dexcom Inc. (DXCM) stake by 358.71% reported in 2018Q3 SEC filing. Westwood Management Corp acquired 78,700 shares as Dexcom Inc. (DXCM)’s stock declined 14.95%. The Westwood Management Corp holds 100,640 shares with $14.40 million value, up from 21,940 last quarter. Dexcom Inc. now has $10.08B valuation. The stock decreased 0.99% or $1.13 during the last trading session, reaching $113.48. About 785,142 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 105.85% since December 20, 2017 and is uptrending. It has outperformed by 105.85% the SP500. Some Historical DXCM News: 27/03/2018 – FDA Authorizes Marketing of the New Dexcom G6® CGM Eliminating Need for Fingerstick Blood Testing for People with Diabetes; 17/05/2018 – DexCom Announces Upcoming Conference Presentation; 27/03/2018 – DEXCOM INC – EXPECTS TO LAUNCH DEXCOM G6 CGM SYSTEMLATER THIS YEAR; 22/05/2018 – DEXCOM Short Thesis; 02/05/2018 – DexCom 1Q Adj Loss/Shr 32c; 08/03/2018 – DEXCOM INC – PTAB RULED 2 EARLY PATENTS HELD BY WAVEFORM ARE NOT INVALID, BASED ON CHALLENGES BROUGHT BY CO; 29/03/2018 – Alger Spectra Adds DexCom, Cuts CBS, Buys More Facebook; 17/05/2018 – VP Leach Gifts 176 Of DexCom Inc; 27/03/2018 – U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM; 08/03/2018 WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents

NUTRAFUELS INC (OTCMKTS:NTFU) had a decrease of 32% in short interest. NTFU’s SI was 8,500 shares in December as released by FINRA. Its down 32% from 12,500 shares previously. With 78,600 avg volume, 0 days are for NUTRAFUELS INC (OTCMKTS:NTFU)’s short sellers to cover NTFU’s short positions. It closed at $0.194 lastly. It is down 0.00% since December 20, 2017 and is . It has by 0.00% the SP500.

NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products to retail and wholesale outlets. The company has market cap of $17.58 million. The companyÂ’s products include sleep spray to support a healthy sleep cycle and improve the quality of restful sleep; energize spray to enhance energy, and restore vigor and vitality; and garcinia cambogia spray, an appetite and weight management spray. It currently has negative earnings. It also offers NRG-X extreme energy spray to enhance energy and stamina; headache and pain spray to relieve headaches and pain; and hair, skin, and nails spray to nourish and encourage hair, skin, and nail growth.

More news for NutraFuels, Inc. (OTCMKTS:NTFU) were recently published by: Globenewswire.com, which released: “Freedom Leaf Inc. Announces National Distribution Agreement Other OTC:FRLF – GlobeNewswire” on February 28, 2018. Globenewswire.com‘s article titled: “Freedom Leaf, Inc Partners With NutraFuels, Inc And Attends Tobacco Product Expo (TPE) In Las Vegas, NV – GlobeNewswire” and published on January 31, 2018 is yet another important article.

Among 11 analysts covering DexCom (NASDAQ:DXCM), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. DexCom had 16 analyst reports since July 2, 2018 according to SRatingsIntel. Berenberg upgraded the shares of DXCM in report on Monday, August 6 to “Buy” rating. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Neutral” rating given on Friday, October 19 by Goldman Sachs. Jefferies maintained it with “Buy” rating and $125 target in Thursday, August 2 report. The firm has “Equal-Weight” rating by Morgan Stanley given on Thursday, October 11. BMO Capital Markets maintained the stock with “Outperformer” rating in Thursday, August 2 report. The firm earned “Buy” rating on Thursday, August 23 by Canaccord Genuity. Bank of America maintained the stock with “Buy” rating in Wednesday, August 15 report. The firm has “Buy” rating given on Thursday, August 2 by Canaccord Genuity. The firm has “Outperform” rating by Robert W. Baird given on Thursday, August 23. Morgan Stanley maintained it with “Equal-Weight” rating and $130 target in Friday, August 3 report.

Investors sentiment increased to 1.31 in 2018 Q3. Its up 0.09, from 1.22 in 2018Q2. It improved, as 12 investors sold DXCM shares while 107 reduced holdings. 84 funds opened positions while 72 raised stakes. 84.12 million shares or 4.99% less from 88.54 million shares in 2018Q2 were reported. Df Dent And Com Inc reported 0.03% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Baillie Gifford Com holds 0.79% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 5.09 million shares. Susquehanna Intl Gp Llp accumulated 1,552 shares or 0% of the stock. Fiduciary Tru invested in 0.02% or 3,925 shares. Schwab Charles Inv Management Incorporated has 338,177 shares for 0.03% of their portfolio. Barclays Public Limited Liability Corp reported 0.01% stake. Accredited Inc holds 0.08% or 2,367 shares. Alabama-based Weiss Multi has invested 0.15% in DexCom, Inc. (NASDAQ:DXCM). 2,135 were reported by Manufacturers Life Insur Company The. Js Lc, a New York-based fund reported 700 shares. Essex Investment Management Lc stated it has 0.29% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Regions Fincl Corp invested in 0.04% or 23,208 shares. Royal Bankshares Of Canada invested in 138,409 shares or 0.01% of the stock. Moreover, Granahan Mgmt Ma has 0.36% invested in DexCom, Inc. (NASDAQ:DXCM) for 46,596 shares. 765 were reported by Pnc Group Inc Incorporated.

Westwood Management Corp decreased Coherent Inc. (NASDAQ:COHR) stake by 1,900 shares to 224,000 valued at $38.57 million in 2018Q3. It also reduced Texas Instruments Inc. (NASDAQ:TXN) stake by 149,090 shares and now owns 90,600 shares. Delphi Technologies Plc was reduced too.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.